The goal of the collaboration is to extend the availability of consulting services to healthcare organizations in the region who are in need of assistance with designing a governance framework for the secondary use of real-world data (RWD) for clinical trials, real-world evidence (RWE) generation, and scientific publications.

"This is an exciting opportunity that combines the expert consulting services of Chrysalis with TriNetX's market-leading platform and global network to benefit research teams and the patients under their care across health systems in Australia and New Zealand," said Nick Northcott, Chrysalis Managing Partner.

TriNetX is the world's largest and fastest growing collaborative research network comprised of healthcare organizations and life sciences companies driving real-world research to accelerate the development of new therapies around the world. TriNetX puts the power of RWD into the hands of its worldwide community to improve protocol design, streamline trial operations, refine safety signals, and enrich RWE generation.

Chrysalis' mission is to enable evidence-based care by supporting health systems with the development of sustainable research and innovation strategies for growth, adherence to governance regulations, improving efficiency and cost effectiveness of operations, as well as serving as a steward of research integrity in compliance with the Code for the Responsible Conduct of Research.

"Our collaboration with Chrysalis can help healthcare organizations who require the development of a new governance framework prior to leveraging real-world data for sponsored and investigator-initiated clinical and observational research," said Niharika Anand, Regional Director, APAC Healthcare Partnerships at TriNetX.